Published in Circ Cardiovasc Qual Outcomes on November 19, 2013
Trial to Assess Chelation Therapy (TACT) | NCT00044213
Trial to Assess Chelation Therapy 2 (TACT2) | NCT02733185
Trial to Assess Chelation Therapy in Critical Limb Ischemia (TACT3a) | NCT03982693
EDTA chelation therapy alone and in combination with oral high-dose multivitamins and minerals for coronary disease: The factorial group results of the Trial to Assess Chelation Therapy. Am Heart J (2014) 1.61
Metal pollutants and cardiovascular disease: mechanisms and consequences of exposure. Am Heart J (2014) 1.06
Heavy Metals, Cardiovascular Disease, and the Unexpected Benefits of Chelation Therapy. J Am Coll Cardiol (2016) 0.82
World health dilemmas: Orphan and rare diseases, orphan drugs and orphan patients. World J Methodol (2014) 0.80
New developments and controversies in iron metabolism and iron chelation therapy. World J Methodol (2016) 0.78
Are concerns about reliability in the trial to assess chelation therapy fair grounds for a hasty dismissal?: An alternative perspective. Circ Cardiovasc Qual Outcomes (2014) 0.78
Chelation therapy and cardiovascular disease: connecting scientific silos to benefit cardiac patients. Trends Cardiovasc Med (2014) 0.76
Cardiology Patient Page. Chelation therapy: a new look at an old treatment for heart disease, particularly in diabetics. Circulation (2015) 0.76
Chelation therapy after the trial to assess chelation therapy: results of a unique trial. Curr Opin Cardiol (2014) 0.76
Supplementation with Phycocyanobilin, Citrulline, Taurine, and Supranutritional Doses of Folic Acid and Biotin-Potential for Preventing or Slowing the Progression of Diabetic Complications. Healthcare (Basel) (2017) 0.75
Antihyperglycemic and antioxidant activities of twig extract from Cinnamomum osmophloeum. J Tradit Complement Med (2015) 0.75
Hyperglycemia Does Not Affect Iron Mediated Toxicity of Cultured Endothelial and Renal Tubular Epithelial Cells: Influence of L-Carnosine. J Diabetes Res (2015) 0.75
Quality-of-life outcomes with a disodium EDTA chelation regimen for coronary disease: results from the trial to assess chelation therapy randomized trial. Circ Cardiovasc Qual Outcomes (2014) 0.75
Chelation therapy to treat atherosclerosis, particularly in diabetes: is it time to reconsider? Expert Rev Cardiovasc Ther (2016) 0.75
Interaction between the Haptoglobin 2 Phenotype and Diabetes Mellitus on Systolic Pulmonary Arterial Pressure and Nitric Oxide Bioavailability in Hemodialysis Patients. J Diabetes Res (2015) 0.75
Standards of medical care in diabetes--2013. Diabetes Care (2013) 24.85
Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med (2011) 10.33
Role of oxidative stress in development of complications in diabetes. Diabetes (1991) 8.27
Effect of disodium EDTA chelation regimen on cardiovascular events in patients with previous myocardial infarction: the TACT randomized trial. JAMA (2013) 5.31
Environmental lead exposure and progression of chronic renal diseases in patients without diabetes. N Engl J Med (2003) 5.18
Non-insulin-dependent diabetes mellitus in minorities in the United States. Ann Intern Med (1996) 4.58
Blood lead below 0.48 micromol/L (10 microg/dL) and mortality among US adults. Circulation (2006) 3.47
Impact of diabetes on long-term prognosis in patients with unstable angina and non-Q-wave myocardial infarction: results of the OASIS (Organization to Assess Strategies for Ischemic Syndromes) Registry. Circulation (2000) 3.12
Clinical review: The role of advanced glycation end products in progression and complications of diabetes. J Clin Endocrinol Metab (2008) 3.00
Lead, cadmium, smoking, and increased risk of peripheral arterial disease. Circulation (2004) 2.83
Cadmium exposure and incident cardiovascular disease. Epidemiology (2013) 2.55
Design of the Trial to Assess Chelation Therapy (TACT). Am Heart J (2012) 2.09
Effect of chelation therapy on progressive diabetic nephropathy in patients with type 2 diabetes and high-normal body lead burdens. Am J Kidney Dis (2012) 1.50
So much writing, so little science: a review of 37 years of literature on edetate sodium chelation therapy. Ann Pharmacother (1993) 1.43
Reduction of the accumulation of advanced glycation end products by ACE inhibition in experimental diabetic nephropathy. Diabetes (2002) 1.36
Treatment of angina pectoris with disodium ethylene diamine tetraacetic acid. Am J Med Sci (1956) 1.34
Unlocking the biology of RAGE in diabetic microvascular complications. Trends Endocrinol Metab (2013) 1.30
Advanced glycation end-product of low density lipoprotein activates the toll-like 4 receptor pathway implications for diabetic atherosclerosis. Arterioscler Thromb Vasc Biol (2008) 1.25
Chelation: a fundamental mechanism of action of AGE inhibitors, AGE breakers, and other inhibitors of diabetes complications. Diabetes (2012) 1.24
The in vivo dissolution of metastatic calcium; an approach to atherosclerosis. Am J Med Sci (1955) 1.14
Angiotensin II receptor antagonists and angiotensin-converting enzyme inhibitors lower in vitro the formation of advanced glycation end products: biochemical mechanisms. J Am Soc Nephrol (2002) 1.13
Low-level environmental exposure to lead unmasked as silent killer. Circulation (2006) 1.02
EDTA chelation effects on urinary losses of cadmium, calcium, chromium, cobalt, copper, lead, magnesium, and zinc. Biol Trace Elem Res (2001) 0.96
Transition metals bind to glycated proteins forming redox active "glycochelates": implications for the pathogenesis of certain diabetic complications. Biochem Biophys Res Commun (1998) 0.96
Chelation therapy: overlooked in the treatment and prevention of diabetes complications? Future Med Chem (2013) 0.94
Transition metals redox: reviving an old plot for diabetic vascular disease. J Clin Invest (2001) 0.92
Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med (2005) 27.36
Complementary and alternative medicine use among adults and children: United States, 2007. Natl Health Stat Report (2008) 19.25
Complementary and alternative medicine use among adults: United States, 2002. Adv Data (2004) 17.17
A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med (2009) 14.13
Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med (2011) 11.99
Strategies for multivessel revascularization in patients with diabetes. N Engl J Med (2012) 10.79
Coronary-artery bypass surgery in patients with left ventricular dysfunction. N Engl J Med (2011) 10.29
Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA (2004) 9.74
Stenting and medical therapy for atherosclerotic renal-artery stenosis. N Engl J Med (2013) 8.91
Coronary intervention for persistent occlusion after myocardial infarction. N Engl J Med (2006) 8.74
Outcomes of anatomical versus functional testing for coronary artery disease. N Engl J Med (2015) 8.70
Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med (2003) 8.65
Ultrafiltration in decompensated heart failure with cardiorenal syndrome. N Engl J Med (2012) 8.28
Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA (2006) 7.81
Coronary bypass surgery with or without surgical ventricular reconstruction. N Engl J Med (2009) 7.71
Spironolactone for heart failure with preserved ejection fraction. N Engl J Med (2014) 7.48
Human susceptibility and resistance to Norwalk virus infection. Nat Med (2003) 7.07
Ethnic differences in coronary calcification: the Multi-Ethnic Study of Atherosclerosis (MESA). Circulation (2005) 6.80
Myocardial viability and survival in ischemic left ventricular dysfunction. N Engl J Med (2011) 6.65
Efficacy and safety of exercise training in patients with chronic heart failure: HF-ACTION randomized controlled trial. JAMA (2009) 6.36
Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med (2008) 6.17
Ginkgo biloba for prevention of dementia: a randomized controlled trial. JAMA (2008) 6.00
Erythropoietic response and outcomes in kidney disease and type 2 diabetes. N Engl J Med (2010) 5.48
Effect of disodium EDTA chelation regimen on cardiovascular events in patients with previous myocardial infarction: the TACT randomized trial. JAMA (2013) 5.31
Effectiveness-based guidelines for the prevention of cardiovascular disease in women--2011 update: a guideline from the american heart association. Circulation (2011) 5.26
Prognostic importance of defibrillator shocks in patients with heart failure. N Engl J Med (2008) 5.13
Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes. JAMA (2004) 5.11
Home use of automated external defibrillators for sudden cardiac arrest. N Engl J Med (2008) 4.64
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. N Engl J Med (2015) 4.56
Stop Hypertension with the Acupuncture Research Program (SHARP): results of a randomized, controlled clinical trial. Hypertension (2006) 4.54
ACC/AHA 2002 guideline update for exercise testing: summary article. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1997 Exercise Testing Guidelines). J Am Coll Cardiol (2002) 4.48
A national survey of provisions in clinical-trial agreements between medical schools and industry sponsors. N Engl J Med (2002) 4.42
Quality of life with defibrillator therapy or amiodarone in heart failure. N Engl J Med (2008) 4.33
Music, imagery, touch, and prayer as adjuncts to interventional cardiac care: the Monitoring and Actualisation of Noetic Trainings (MANTRA) II randomised study. Lancet (2005) 4.29
Depression as a risk factor for mortality after coronary artery bypass surgery. Lancet (2003) 4.21
Evidence-based guidelines for cardiovascular disease prevention in women: 2007 update. Circulation (2007) 4.16
Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study. Circulation (2004) 4.04
Adverse effect of ventricular pacing on heart failure and atrial fibrillation among patients with normal baseline QRS duration in a clinical trial of pacemaker therapy for sinus node dysfunction. Circulation (2003) 3.97
Clinical and economic implications of the Multicenter Automatic Defibrillator Implantation Trial-II. Ann Intern Med (2005) 3.83
Impact of National Clinical Guideline recommendations for revascularization of persistently occluded infarct-related arteries on clinical practice in the United States. Arch Intern Med (2011) 3.73
2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2008) 3.70
Atrial high rate episodes detected by pacemaker diagnostics predict death and stroke: report of the Atrial Diagnostics Ancillary Study of the MOde Selection Trial (MOST). Circulation (2003) 3.57
The rationale and design of the Surgical Treatment for Ischemic Heart Failure (STICH) trial. J Thorac Cardiovasc Surg (2007) 3.45
Effect of an implantable gentamicin-collagen sponge on sternal wound infections following cardiac surgery: a randomized trial. JAMA (2010) 3.39
Evidence-based guidelines for cardiovascular disease prevention in women. Circulation (2004) 3.39
Ventricular pacing or dual-chamber pacing for sinus-node dysfunction. N Engl J Med (2002) 3.35
Heart failure and a controlled trial investigating outcomes of exercise training (HF-ACTION): design and rationale. Am Heart J (2007) 3.34
Early menopause predicts future coronary heart disease and stroke: the Multi-Ethnic Study of Atherosclerosis. Menopause (2012) 3.32
Inducible myocardial ischemia and outcomes in patients with coronary artery disease and left ventricular dysfunction. J Am Coll Cardiol (2013) 3.15
Safety and efficacy of a totally subcutaneous implantable-cardioverter defibrillator. Circulation (2013) 3.14
Oral high-dose multivitamins and minerals after myocardial infarction: a randomized trial. Ann Intern Med (2013) 3.08
Recruitment strategies in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol (2007) 2.98
Limitations of ejection fraction for prediction of sudden death risk in patients with coronary artery disease: lessons from the MUSTT study. J Am Coll Cardiol (2007) 2.90
Effectiveness-based guidelines for the prevention of cardiovascular disease in women--2011 update: a guideline from the American Heart Association. J Am Coll Cardiol (2011) 2.89
Impact of collateral flow to the occluded infarct-related artery on clinical outcomes in patients with recent myocardial infarction: a report from the randomized occluded artery trial. Circulation (2010) 2.88
Provision of spiritual care to patients with advanced cancer: associations with medical care and quality of life near death. J Clin Oncol (2009) 2.85
Effects of intensive versus moderate lipid-lowering therapy on myocardial ischemia in older patients with coronary heart disease: results of the Study Assessing Goals in the Elderly (SAGE). Circulation (2007) 2.82
Minimizing ventricular pacing to reduce atrial fibrillation in sinus-node disease. N Engl J Med (2007) 2.79
CPAP versus oxygen in obstructive sleep apnea. N Engl J Med (2014) 2.75
Cost-effectiveness of defibrillator therapy or amiodarone in chronic stable heart failure: results from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). Circulation (2006) 2.60
Impact of implantable cardioverter-defibrillator, amiodarone, and placebo on the mode of death in stable patients with heart failure: analysis from the sudden cardiac death in heart failure trial. Circulation (2009) 2.57